These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 18632601)

  • 1. A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model.
    Menu E; Garcia J; Huang X; Di Liberto M; Toogood PL; Chen I; Vanderkerken K; Chen-Kiang S
    Cancer Res; 2008 Jul; 68(14):5519-23. PubMed ID: 18632601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6.
    Baughn LB; Di Liberto M; Wu K; Toogood PL; Louie T; Gottschalk R; Niesvizky R; Cho H; Ely S; Moore MA; Chen-Kiang S
    Cancer Res; 2006 Aug; 66(15):7661-7. PubMed ID: 16885367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolonged early G(1) arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4.
    Huang X; Di Liberto M; Jayabalan D; Liang J; Ely S; Bretz J; Shaffer AL; Louie T; Chen I; Randolph S; Hahn WC; Staudt LM; Niesvizky R; Moore MA; Chen-Kiang S
    Blood; 2012 Aug; 120(5):1095-106. PubMed ID: 22718837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma.
    Ely S; Di Liberto M; Niesvizky R; Baughn LB; Cho HJ; Hatada EN; Knowles DM; Lane J; Chen-Kiang S
    Cancer Res; 2005 Dec; 65(24):11345-53. PubMed ID: 16357141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pure antiestrogen-induced G1-arrest in myeloma cells results from the reduced kinase activity of cyclin D3/CDK6 complexes whereas apoptosis is mediated by endoplasmic reticulum-dependent caspases.
    Gauduchon J; Seguin A; Marsaud V; Clay D; Renoir JM; Sola B
    Int J Cancer; 2008 May; 122(9):2130-41. PubMed ID: 18183592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY; Dai Y; Grant S
    Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support.
    Li J; Favata M; Kelley JA; Caulder E; Thomas B; Wen X; Sparks RB; Arvanitis A; Rogers JD; Combs AP; Vaddi K; Solomon KA; Scherle PA; Newton R; Fridman JS
    Neoplasia; 2010 Jan; 12(1):28-38. PubMed ID: 20072651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CDK4/6 Inhibitor PD 0332991 Sensitizes Acute Myeloid Leukemia to Cytarabine-Mediated Cytotoxicity.
    Yang C; Boyson CA; Di Liberto M; Huang X; Hannah J; Dorn DC; Moore MA; Chen-Kiang S; Zhou P
    Cancer Res; 2015 May; 75(9):1838-45. PubMed ID: 25744718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma.
    Raje N; Hideshima T; Mukherjee S; Raab M; Vallet S; Chhetri S; Cirstea D; Pozzi S; Mitsiades C; Rooney M; Kiziltepe T; Podar K; Okawa Y; Ikeda H; Carrasco R; Richardson PG; Chauhan D; Munshi NC; Sharma S; Parikh H; Chabner B; Scadden D; Anderson KC
    Leukemia; 2009 May; 23(5):961-70. PubMed ID: 19151776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
    Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
    J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.
    Niesvizky R; Badros AZ; Costa LJ; Ely SA; Singhal SB; Stadtmauer EA; Haideri NA; Yacoub A; Hess G; Lentzsch S; Spicka I; Chanan-Khan AA; Raab MS; Tarantolo S; Vij R; Zonder JA; Huang X; Jayabalan D; Di Liberto M; Huang X; Jiang Y; Kim ST; Randolph S; Chen-Kiang S
    Leuk Lymphoma; 2015; 56(12):3320-8. PubMed ID: 25813205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pan-histone deacetylase inhibitor CR2408 disrupts cell cycle progression, diminishes proliferation and causes apoptosis in multiple myeloma cells.
    Baumann P; Junghanns C; Mandl-Weber S; Strobl S; Oduncu F; Schmidmaier R
    Br J Haematol; 2012 Mar; 156(5):633-42. PubMed ID: 22211565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting phospho-MARCKS overcomes drug-resistance and induces antitumor activity in preclinical models of multiple myeloma.
    Yang Y; Chen Y; Saha MN; Chen J; Evans K; Qiu L; Reece D; Chen GA; Chang H
    Leukemia; 2015 Mar; 29(3):715-26. PubMed ID: 25179733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ShRNA-mediated Bmi-1 silencing sensitizes multiple myeloma cells to bortezomib.
    Wu SQ; Xu ZZ; Niu WY; Huang HB; Zhan R
    Int J Mol Med; 2014 Aug; 34(2):616-23. PubMed ID: 24913180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vorinostat enhances the antimyeloma effects of melphalan and bortezomib.
    Campbell RA; Sanchez E; Steinberg J; Shalitin D; Li ZW; Chen H; Berenson JR
    Eur J Haematol; 2010 Mar; 84(3):201-11. PubMed ID: 19929977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bortezomib and IL-12 produce synergetic anti-multiple myeloma effects with reduced toxicity to natural killer cells.
    Wang X; Feng X; Wang J; Shao N; Ji C; Ma D; Henter JI; Fadeel B; Zheng C
    Anticancer Drugs; 2014 Mar; 25(3):282-8. PubMed ID: 24300915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapeutic agents in gastric cancer cell lines.
    Bae SH; Ryoo HM; Kim MK; Lee KH; Sin JI; Hyun MS
    Oncol Rep; 2008 Apr; 19(4):1027-32. PubMed ID: 18357392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan.
    Sanchez E; Li M; Steinberg JA; Wang C; Shen J; Bonavida B; Li ZW; Chen H; Berenson JR
    Br J Haematol; 2010 Feb; 148(4):569-81. PubMed ID: 19958357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arsenic trioxide and 2-methoxyestradiol reduce beta-catenin accumulation after proteasome inhibition and enhance the sensitivity of myeloma cells to Bortezomib.
    Zhou L; Hou J; Fu W; Wang D; Yuan Z; Jiang H
    Leuk Res; 2008 Nov; 32(11):1674-83. PubMed ID: 18485479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.
    Raub TJ; Wishart GN; Kulanthaivel P; Staton BA; Ajamie RT; Sawada GA; Gelbert LM; Shannon HE; Sanchez-Martinez C; De Dios A
    Drug Metab Dispos; 2015 Sep; 43(9):1360-71. PubMed ID: 26149830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.